View all the latest information in myeloproliferative neoplasms, arranged by trials and clinical studies. Listed below are recently added trial updates.
Polycythemia vera and essential thrombocythemia: 2021 updates
In a recent publication in the American Journal of Hematology, Tefferi and Barbui provided a review of the 2021 updates on the diagnosis,...
Coupling germline genetics to interferon-alpha responses in polycythemia vera treatment
Pegylated interferon alfa-2 (PEG-IFN) induces high response rates in many patients with polycythemia vera (PV),...
Educational theme: The role of interferon-alpha in the treatment of MPN
Interferons (IFN) are cytokines released by host cells to induce innate immune response against viral infections and are...
Results of the phase II trial Low-PV: Ropeginterferon versus phlebotomy for low risk PV
At the 25th European Hematology Association (EHA) Annual Congress, our Steering Committee member Tiziano Barbui...
New drug application (NDA) for accelerated FDA approval to be submitted for pacritinib in treating myelofibrosis with severe thrombocytopenia
The U.S Food and Drug Administration (FDA) has agreed to a...
Results from the PAC203 phase II trial: pacritinib dose recommendation in thrombocytopenic patients with MF
During the 61st American Society of Hematology Annual Meeting & Exposition (ASH 2019),...
Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms
The bone marrow niche is the local tissue microenvironment that maintains and regulates stem...
Real-world experience with ruxolitinib in myelofibrosis
Ruxolitinib is a Janus kinase (JAK) 1 and JAK 2 inhibitor approved for primary and secondary intermediate-/high-risk myelofibrosis (MF). The...